Silence Therapeutics (SLN) Equity Ratio: 2019-2025
Historic Equity Ratio for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to 0.50.
- Silence Therapeutics' Equity Ratio fell 51.10% to 0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.50, marking a year-over-year decrease of 51.10%. This contributed to the annual value of 0.66 for FY2024, which is 259.22% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Equity Ratio is 0.50, which was down 11.46% from 0.57 recorded in Q2 2025.
- Silence Therapeutics' 5-year Equity Ratio high stood at 1.03 for Q3 2024, and its period low was 0.18 during Q4 2023.
- Over the past 3 years, Silence Therapeutics' median Equity Ratio value was 0.63 (recorded in 2024), while the average stood at 0.69.
- As far as peak fluctuations go, Silence Therapeutics' Equity Ratio plummeted by 81.59% in 2023, and later soared by 259.22% in 2024.
- Quarterly analysis of 5 years shows Silence Therapeutics' Equity Ratio stood at 1.00 in 2021, then remained steady at 1.00 in 2022, then plummeted by 81.59% to 0.18 in 2023, then spiked by 259.22% to 0.66 in 2024, then crashed by 51.10% to 0.50 in 2025.
- Its Equity Ratio was 0.50 in Q3 2025, compared to 0.57 in Q2 2025 and 0.61 in Q1 2025.